The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A three-dimensional human neural cell culture model of Alzheimer’s disease
Open accessAbstract
Alzheimer's disease is the most common form of dementia, characterized by two pathological hallmarks: amyloid-β plaques and neurofibrillary tangles. The amyloid hypothesis of Alzheimer's disease posits that the excessive accumulation of amyloid-β peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau. However, to date, no single disease model has serially linked these two pathological events using human neuronal cells. Mouse models with familial Alzheimer's disease (FAD) mutations exhibit amyloid-β-induced synaptic and memory deficits but they do not fully recapitulate other key pathological events of Alzheimer's disease, including distinct neurofibrillary tangle pathology. Human neurons derived from Alzheimer's disease patients have shown elevated levels of toxic amyloid-β species and phosphorylated tau but did not demonstrate amyloid-β plaques or neurofibrillary tangles. Here we report that FAD mutations in β-amyloid precursor protein and presenilin 1 are able to induce robust extracellular deposition of amyloid-β, including amyloid-β plaques, in a human neural stem-cell-derived three-dimensional (3D) culture system. More importantly, the 3D-differentiated neuronal cells expressing FAD mutations exhibited high levels of detergent-resistant, silver-positive aggregates of phosphorylated tau in the soma and neurites, as well as filamentous tau, as detected by immunoelectron microscopy. Inhibition of amyloid-β generation with β- or γ-secretase inhibitors not only decreased amyloid-β pathology, but also attenuated tauopathy. We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-β-mediated tau phosphorylation. We have successfully recapitulated amyloid-β and tau pathology in a single 3D human neural cell culture system. Our unique strategy for recapitulating Alzheimer's disease pathology in a 3D neural cell culture model should also serve to facilitate the development of more precise human neural cell models of other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beading or blebbing in neurites is a marker of dystrophic neurites in the AD brain (3, 42, 43).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, tau protein becomes hyperphosphorylated, resulting in tau dissociating from microtubules and forming insoluble tau aggregates in the neurites and cell bodies (3, 37).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points (Choi et al., 2014, Israel et al., 2012, Moore et al., 2015, Muratore et al., 2014, Ochalek et al., 2017, Shi et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Choi et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Modeling these pathological hallmarks has largely relied on transgenic cellular and animal models harboring genetic mutations linked to ADAD (3–5).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“As for human neurons, previous studies focused on overexpressing mutant APP and Presenilin in REN stem cells grown in a 3D culture (3), which differs from patient-specific LOAD model that relies on the endogenous recapitulation of AD-associated phenotypes as provided in this study.”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
In the citing paper
“one study revealed that familial AD (FAD) mutations in β-amyloid precursor protein and presenilin 1 induced robust extracellular deposition of amyloid-β in a human neural stem-cell-derived 3D culture system85.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [85]
In the citing paper
“the 3D-differentiated neuronal cells expressing FAD mutations exhibited aggregates of phosphorylated tau as well as filamentous tau.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [85]
In the citing paper
“A 3D in vitro culture system consisting of human neurons differentiated from induced pluripotent stem cells overexpressing human APP containing FAD mutations generates robust Aβ42 production and amyloid deposition. Importantly, this model also develops elevated phospho-tau levels and fibrillary tau aggregates, suggesting that elevated Aβ levels alone are sufficient to drive tau pathology in human”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Choi et al., 2014
In the citing paper
“It was recently shown that development of a 3D culture of human neural stem cells transfected with APPK670N/M671L/V717I and PS1ΔE9 in Matrigel scaffolding resulted in the extracellular aggregation of Aβ into plaques and the intracellular aggregation of tau in dystrophic neurites and the cell soma [23, 77].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationProbing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C., Lee, V. M. ‐., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,211
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
Modeling familial Alzheimer's disease with induced pluripotent stem cells
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., & Suzuki, N. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr394 · Cited by 599
Cohen, R. M., Rezai-Zadeh, K. P., Weitz, T. M., Rentsendorj, A., Gate, D., Spivak, I. E., Bholat, Y., Vasilevko, V., Glabe, C. G., Breunig, J. J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3672-12.2013 · Cited by 555
Muratore, C. R., Rice, H. C., Srikanth, P., Callahan, D. G., Shin, T., Benjamin, L. N. P., Walsh, D. M., Selkoe, D. J., & Young-Pearse, T. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu064 · Cited by 379
Research works printed but not linked: 1
- Higuchi, M., Trojanowski, J. Q. & Lee, V. M.-Y. Tau protein and tauopathy. Neuropsychopharmacology: The Fifth Generation of Progress (eds Davis, K. L., Charney, D., Coyle, J. T. & Nemeroff, C. ) 1339–1354 (Lippincott, Williams & Wilkins, 2002)
Cited by
Sorted by citations
Items 201–300 of 998
Functional and Mechanistic Neurotoxicity Profiling Using Human iPSC-Derived Neural 3D Cultures
Sirenko, O., Parham, F., Dea, S., Sodhi, N., Biesmans, S., Mora-Castilla, S., Ryan, K., Behl, M., Chandy, G., Crittenden, C., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy218 · Cited by 84
Faustino, C. M. C., Rijo, P. M., & Reis, C. P. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.020 · Cited by 82
Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 84
Microvascular Alterations in Alzheimer's Disease
Steinman, J., Sun, H., & Feng, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.618986 · Cited by 85
Krell‐Roesch, J., Lowe, V. J., Neureiter, J., Pink, A., Roberts, R. O., Mielke, M. M., Vemuri, P., Stokin, G. B., Christianson, T. J. H., Jack, C. R., et al. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217002368 · Cited by 81
Feng, M.-G., Liu, C.-F., Chen, L., Feng, W.-B., Liu, M., Hai, H., & Lu, J.-M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.043 · Cited by 80
Hernández, D., Rooney, L. A., Daniszewski, M., Gulluyan, L. M., Liang, H. H., Cook, A. L., Hewitt, A. W., & Pébay, A. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10147-5 · Cited by 79
Modeling Neurodegenerative Microenvironment Using Cortical Organoids Derived from Human Stem Cells
Yan, Y., Song, L., Bejoy, J., Zhao, J., Kanekiyo, T., Bu, G., Zhou, Y., & Li, Y. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0423 · Cited by 84
Translating the Science of Aging into Therapeutic Interventions
Kirkland, J. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025908 · Cited by 78
Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?
Eglen, R. M., & Randle, D. H. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.647 · Cited by 79
Krishtal, J., Bragina, O., Metsla, K., Palumaa, P., & Tõugu, V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186636 · Cited by 76
Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming
Sun, Z., Kwon, J.-S., Ren, Y., Chen, S., Walker, C. K., Lu, X., Cates, K., Karahan, H., Sviben, S., Fitzpatrick, J. A. J., et al. (2024) · Science · doi:10.1126/science.adl2992 · Cited by 77
Self-citationBhattacharyya, R., Black, S. E., Lotlikar, M. S., Fenn, R. H., Jorfi, M., Kovacs, D. M., & Tanzi, R. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109134 · Cited by 77
Self-citationBrain organoids: a next step for humanized Alzheimer’s disease models?
Gerakis, Y., & Hetz, C. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0343-7 · Cited by 64
Neural Lineage Differentiation From Pluripotent Stem Cells to Mimic Human Brain Tissues
Hong, Y. J., & Tae, J. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00400 · Cited by 78
Takahashi, H., & Okano, T. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500194 · Cited by 77
Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease
Pitcairn, C., Wani, W. Y., & Mazzulli, J. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.008 · Cited by 75
Wu, Y., Chiu, F., Yeh, C.-S., & Kuo, H. (2019) · Open Biology · doi:10.1098/rsob.180177 · Cited by 78
Wu, Q., Shaikh, M., Meymand, E. S., Zhang, B., Luk, K. C., Trojanowski, J. Q., & Lee, V. M. ‐. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02227-6 · Cited by 71
Neuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
Watson, P. M. D., Kavanagh, E., Allenby, G., & Vassey, M. (2017) · SLAS Discovery · doi:10.1177/2472555217691450 · Cited by 74
Low-Level Light in Combination with Metabolic Modulators for Effective Therapy of Injured Brain
Dong, T., Zhang, Q., Hamblin, M. R., & Wu, M. X. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.87 · Cited by 75
Medda, X., Mertens, L., Versweyveld, S., Diels, A., Barnham, L., Bretteville, A., Buist, A., Verheyen, A., Royaux, I. E., Ebneth, A., et al. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116638029 · Cited by 74
Zhang, D., Zhang, W., Chen, M., Gao, X., Yuan, H., Lin, X., Mao, X., Wang, C., Guo, X., Du, Y., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.02.017 · Cited by 75
Liu, Z., Pouli, D., Sood, D., Sundarakrishnan, A., Mingalone, C. K. H., Arendt, L. M., Alonzo, C., Quinn, K. P., Kuperwasser, C., Zeng, L., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.041 · Cited by 72
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Xia, Z., Prescott, E. E., Urbanek, A., Wareing, H. E., King, M. C., Olerinyova, A., Dakin, H., Leah, T., Barnes, K. A., Matuszyk, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49028-z · Cited by 67
Acoustofluidic assembly of 3D neurospheroids to model Alzheimer's disease
Cai, H., Ao, Z., Hu, L., Moon, Y., Wu, Z., Lu, H.-C., Kim, J., & Guo, F. (2020) · The Analyst · doi:10.1039/d0an01373k · Cited by 70
Zhang, Y. S., & Khademhosseini, A. (2015) · Nanomedicine · doi:10.2217/nnm.15.18 · Cited by 71
Towards Advanced iPSC-based Drug Development for Neurodegenerative Disease
Pasteuning-Vuhman, S., de Jongh, R., Timmers, A., & Pasterkamp, R. J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.013 · Cited by 72
Ribarič, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063245 · Cited by 77
Talwar, P., Sinha, J., Grover, S., Rawat, C., Kushwaha, S. S., Agarwal, R., Taneja, V., & Kukreti, R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9390-0 · Cited by 71
Velagapudi, R., Lepiarz‐Raba, I., El‐Bakoush, A., Katola, F. O., Bhatia, H. S., Fiebich, B. L., & Olajide, O. A. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201801237 · Cited by 75
The Role of P2X7 Receptor in Alzheimer’s Disease
Francistiová, L., Bianchi, C., Lauro, C. D., Sebastián‐Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00094 · Cited by 73
Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69
Utilizing stem cells for three-dimensional neural tissue engineering
Knowlton, S. M., Cho, Y. K., Li, X. J., Khademhosseini, A., & Taşoğlu, S. (2016) · Biomaterials Science · doi:10.1039/c5bm00324e · Cited by 69
Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease
Naqvi, A. A. T., Hasan, G. M., & Hassan, M. I. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200106125910 · Cited by 70
Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research
Langley, G., Austin, C. P., Balapure, A. K., Birnbaum, L. S., Bucher, J. R., helen, F. J., Fitzpatrick, S. C., Fowle, J. R., Kavlock, R. J., Kitano, H., et al. (2015) · Environmental Health Perspectives · doi:10.1289/ehp.1510345 · Cited by 69
Modeling Late-Onset Sporadic Alzheimer’s Disease through BMI1 Deficiency
Flamier, A., El Hajjar, J., Adjaye, J., Fernandes, K. J., Abdouh, M., & Bernier, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.097 · Cited by 65
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain
Blanchard, J., Victor, M. B., & Tsai, L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00578-6 · Cited by 68
Song, G., Liu, J., Wang, Q., Wang, D., Chu, B., Li, L., Xiao, G., Gong, J., & Zheng, F. (2021) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2021.107420 · Cited by 67
Koroleva, A., Deiwick, A., El-Tamer, A., Koch, L., Shi, Y., Estévez-Priego, E., Ludl, A.-A., Soriano, J., Guseva, D., Ponimaskin, E. G., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c16616 · Cited by 66
Nakamura, M., Shiozawa, S., Tsuboi, D., Amano, M., Watanabe, H., Maeda, S., Kimura, T., Yoshimatsu, S., Kisa, F., Karch, C. M. M., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.08.011 · Cited by 64
Capano, L. S., Sato, C., Ficulle, E., Yu, A., Horie, K., Kwon, J.-S., Burbach, K. F., Barthélemy, N. R., Fox, S. G., Karch, C. M., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.04.018 · Cited by 65
rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies
Croft, C. L., Cruz, P. E., Ryu, D. H., Ceballos‐Diaz, C., Strang, K. H., Woody, B. M., Lin, W.-L., Deture, M. A., Rodríguez-Lebrón, E., Dickson, D. W., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182184 · Cited by 65
Nierode, G. J., Perea, B., McFarland, S., Pascoal, J. F., Clark, D. S., Schaffer, D. V., & Dordick, J. S. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.10.001 · Cited by 63
Advances in development of exosomes for ophthalmic therapeutics
Tian, Y., Zhang, T., Li, J., & Tao, Y. K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114899 · Cited by 65
Ji, Y., Chen, X., Wang, Z., Meek, C. J., McLean, J. L., Yang, Y., Yuan, C., Rochet, J., Liu, F., & Xu, R. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03041-w · Cited by 74
Colloidal quantum dot hybrids: an emerging class of materials for ambient lighting
Li, B., Lu, M., Feng, J., Zhang, J., Smowton, P. M., Sohn, J. I., Park, I., Zhong, H., & Hou, B. (2020) · Journal of Materials Chemistry C · doi:10.1039/d0tc01349h · Cited by 67
Chun, H., Marriott, I., Lee, C. J., & Cho, H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00797 · Cited by 77
Revisiting rodent models: Octodon degus as Alzheimer’s disease model?
Steffen, J., Krohn, M., Paarmann, K., Schwitlick, C., Brüning, T., Marreiros, R., Müller-Schiffmann, A., Korth, C., Braun, K., & Pahnke, J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0363-y · Cited by 62
Dubey, S. K., Munnangi, S. R., Krishna, K. V., Saha, R. N., Singhvi, G., Agrawal, M., Ajazuddin, M., Saraf, S., Saraf, S., & Alexander, A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00653-z · Cited by 64
Modelling neurodegenerative diseases with 3D brain organoids
Chang, Y., Kim, J., Park, H., Choi, H. G., & Kim, J. (2020) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12626 · Cited by 69
Blood–brain barrier (BBB)-on-a-chip: a promising breakthrough in brain disease research
Peng, B., Hao, S., Tong, Z., Bai, H., Pan, S., Lim, K., Li, L., Voelcker, N. H., & Huang, W. (2022) · Lab on a Chip · doi:10.1039/d2lc00305h · Cited by 61
A novel lysosome‐to‐mitochondria signaling pathway disrupted by amyloid‐β oligomers
Norambuena, A., Wallrabe, H., Cao, R., Wang, D. B., Silva, A., Svindrych, Z., Periasamy, A., Hu, S., Tanzi, R. E., Kim, D. Y., et al. (2018) · The EMBO Journal · doi:10.15252/embj.2018100241 · Cited by 61
Self-citationTau neurotoxicity and rescue in animal models of human Tauopathies
Krüger, L., & Mandelkow, E. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.004 · Cited by 63
The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells
Cai, W., Wu, T., & Chen, N. (2023) · Biomolecules · doi:10.3390/biom13020313 · Cited by 69
Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation
Reilly, P., Winston, C. N., Baron, K. R., Trejo, M., Rockenstein, E. M., Akers, J. C., Kfoury, N., Diamond, M. I., Masliah, E., Rissman, R. A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.005 · Cited by 61
Dunning, C. J. R., McGauran, G., Willén, K. I., Gouras, G. K., O’Connell, D. J., & Linse, S. S. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00262 · Cited by 62
Progression of Seed‐Induced A β Deposition within the Limbic Connectome
Ye, L., Hamaguchi, T., Fritschi, S. K., Eisele, Y. S., Obermüller, U., Jucker, M., & Walker, L. C. (2015) · Brain Pathology · doi:10.1111/bpa.12252 · Cited by 60
Schwamborn, J. C. (2018) · Stem Cells and Development · doi:10.1089/scd.2017.0289 · Cited by 62
Lopez‐Barbosa, N., Garcia, J. G., Cifuentes, J., Castro, L. M., Vargas, F., Ostos, C., Cardona‐Gómez, G. P., Hernández, A. M., & Cruz, J. C. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1775724 · Cited by 59
Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System
Shyam, R., Ren, Y., Lee, J., Braunstein, K. E., Mao, H.-Q., & Wong, P. C. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.15 · Cited by 58
Cellular self-assembly and biomaterials-based organoid models of development and diseases
Shah, S. B., & Singh, A. K. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.01.075 · Cited by 60
Yin, J., & VanDongen, A. M. J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01583 · Cited by 63
LncRNAs: macromolecules with big roles in neurobiology and neurological diseases
Chen, Y., & Zhou, J. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-9965-8 · Cited by 57
Novel fragile X syndrome 2D and 3D brain models based on human isogenic FMRP-KO iPSCs.
Brighi, C., Salaris, F., Soloperto, A., Cordella, F., Ghirga, S., de Turris, V., Rosito, M., Porceddu, P. F., D’Antoni, C., Reggiani, A., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03776-8 · Cited by 56
Venkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 55
Human 3D brain organoids: steering the demolecularization of brain and neurological diseases
Adlakha, Y. K. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01523-w · Cited by 63
Back and forth in time: Directing age in iPSC-derived lineages
Cornacchia, D., & Studer, L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.11.013 · Cited by 56
Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases
Irwin, M. H., Moos, W. H., Faller, D. V., Steliou, K., & Pinkert, C. A. (2016) · Drug Development Research · doi:10.1002/ddr.21294 · Cited by 57
Somatic mutations in neurons during aging and neurodegeneration
Verheijen, B. M., Vermulst, M., & van Leeuwen, F. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1850-y · Cited by 60
Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models
Cenini, G., Hebisch, M., Iefremova, V., Flitsch, L. J., Breitkreuz, Y., Tanzi, R. E., Kim, D. Y., Peitz, M., & Brüstle, O. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103568 · Cited by 60
Self-citationNovotny, R., Langer, F., Mahler, J., Skodras, A., Vlachos, A., Wegenast‐Braun, B. M., Kaeser, S. A., Neher, J. J., Eisele, Y. S., Pietrowski, M. J., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0258-16.2016 · Cited by 55
Simpson, L. W., Good, T. A., & Leach, J. B. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107573 · Cited by 58
γ-Secretase and its modulators: Twenty years and beyond
Xia, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.011 · Cited by 54
Bang, S., Lee, S., Choi, N., & Kim, H. N. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002119 · Cited by 57
Self-citation3D hydrogel models of the neurovascular unit to investigate blood–brain barrier dysfunction
Potjewyd, G., Kellett, K. A. B., & Hooper, N. M. (2021) · Neuronal Signaling · doi:10.1042/ns20210027 · Cited by 53
Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression
Koh, H., Lee, S., Lee, H., Min, J.-W., Iwatsubo, T., Teunissen, C. E., Cho, H., & Ryu, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313136 · Cited by 58
Self-citationKajtez, J., Wesseler, M. F., Birtele, M., Khorasgani, F. R., Ottosson, D. R., Heiskanen, A. R., Kamperman, T., Leijten, J., Martı́nez-Serrano, A., Larsen, N. B., et al. (2022) · Advanced Science · doi:10.1002/advs.202201392 · Cited by 54
Poon, A., Zhang, Y., Chandrasekaran, A., Phanthong, P., Schmid, B., Nielsen, T. T., & Freude, K. (2017) · New Biotechnology · doi:10.1016/j.nbt.2017.05.009 · Cited by 54
Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons
Robbins, J. P., Perfect, L., Ribé, E. M., Maresca, M., Dangla-Valls, A., Foster, E. M., Killick, R., Nowosiad, P., Reid, M. J., Polit, L. D., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00504 · Cited by 53
Biomaterials and Culture Systems for Development of Organoid and Organ-on-a-Chip Models
D’Costa, K. A., Kosic, M., Lam, A., Moradipour, A., Zhao, Y., & Radisic, M. (2020) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02498-w · Cited by 54
Chen, X., Salehi, A., Pearn, M. L., Overk, C., Nguyen, P. D., Kleschevnikov, A. M., Maccecchini, M. L., & Mobley, W. C. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12185 · Cited by 55
In Vivo Chimeric Alzheimer’s Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons
Najm, R., Zalocusky, K. A., Zilberter, M., Yoon, S. Y., Hao, Y., Koutsodendris, N., Nelson, M., Rao, A., Taubes, A., Jones, E. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107962 · Cited by 52
Systems biology of neurodegenerative diseases
Wood, L. B., Winslow, A. R., & Strasser, S. D. (2015) · Integrative Biology · doi:10.1039/c5ib00031a · Cited by 56
Yildirimer, L., Zhang, Q., Kuang, S., Cheung, J. C., Chu, K. A., He, Y., Yang, M., & Zhao, X. (2019) · Biofabrication · doi:10.1088/1758-5090/ab17aa · Cited by 54
3D spheroids of human placenta-derived mesenchymal stem cells attenuate spinal cord injury in mice
Deng, J., Li, M., Meng, F., Liu, Z., Wang, S., Zhang, Y., Li, M., Li, Z., Zhang, L., & Tang, P. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04398-w · Cited by 51
Role of primary aging hallmarks in Alzheimer´s disease
Zhao, J., & Huai, J. (2022) · Theranostics · doi:10.7150/thno.79535 · Cited by 55
Maniv, I., Sarji, M., Bdarneh, A., Feldman, A., Ankawa, R., Koren, E., Magid-Gold, I., Reis, N., Soteriou, D., Salomon‐Zimri, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41545-7 · Cited by 54
Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease
Chiarini, A., Armato, U., Liu, D., & Dal Prà, I. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00134 · Cited by 51
Organoid assessment technologies
Gu, Y., Zhang, W. C., Wu, X., Zhang, Y., Xu, K., & Su, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1499 · Cited by 53
Chen, M., Lee, H. K., Moo, L. R., Hanlon, E. B., Stein, T. D., & Xia, W. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.032 · Cited by 53
All Together Now: Modeling the Interaction of Neural With Non-neural Systems Using Organoid Models
Chukwurah, E., Osmundsen, A. M., Davis, S. W., & Lizarraga, S. B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00582 · Cited by 51
Rodriguez, S., Şahin, A., Schrank, B. R., Lawati, H. J. A., Costantino, I. M., Benz, E. G., Fard, D., Albers, A. D., Cao, L., Gomez, A. C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4699 · Cited by 58
Acharya, P., Choi, N. Y., Shrestha, S., Jeong, S., & Lee, M. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28606 · Cited by 50
Induced pluripotent stem cells as a discovery tool for Alzheimer׳s disease
Sullivan, S. E., & Young-Pearse, T. L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.10.005 · Cited by 50
Probing disorders of the nervous system using reprogramming approaches
Ichida, J. K., & Kiskinis, E. (2015) · The EMBO Journal · doi:10.15252/embj.201591267 · Cited by 51
Coşacak, M. İ., Bhattarai, P., Bocova, L., Dzewas, T., Mashkaryan, V., Papadimitriou, C., Brandt, K., Hollak, H., Antos, C. L., & Kızıl, Ç. (2017) · Scientific Reports · doi:10.1038/s41598-017-13311-5 · Cited by 53
Ma, C., Su, J., Sun, Y., Feng, Y., Shen, N., Li, B., Liang, Y., Yang, X., Wu, H., Zhang, H., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201912399 · Cited by 50
Self-citationModeling neurological disorders using brain organoids
Zhang, D. Y., Song, H., & Ming, G. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.026 · Cited by 54
Metadata
- Authors
- Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., Klee, J. B., Zhang, C., Wainger, B. J., Peitz, M., Kovacs, D. M., Woolf, C. J., Wagner, S. L., Tanzi, R. E., & Kim, D. Y.
- Affiliations
- Harvard University (US)
- University of Bonn (DE)
- Boston Children's Hospital (US)
- Whitehead Institute for Biomedical Research (US)
- University of California San Diego (US)
- Corresponding author
- Tanzi, Rudolph E.
- Kim, Doo Yeon
- ORCID
- Venue
- Nature
- Published
- 2014-10-12
- Volume
- 515
- Issue
- 7526
- Pages
- 274-278
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4366007
- OpenAlex
- W2126231259
- Cited by
- 1,195
- References
- 30
- Citations by year
- 2026: 67 · 2025: 75 · 2024: 95 · 2023: 88 · 2022: 112 · 2021: 111 · 2020: 141 · 2019: 109 · 2018: 109 · 2017: 87 · 2016: 97 · 2015: 87 · 2014: 14
- FWCI
- 63.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Massachusetts General Hospital
- Cure Alzheimer's Fund
- University of Edinburgh
- National Institute on Aging (5P01 AG15379, P01AG015379, R21AG031483, RF1AG048080, P50AG005134, R01AG014713, P01AG004953, P30AG062421)
- National Institute of Mental Health (R37MH060009)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK057521, P30DK043351)
- National Institute of Neurological Disorders and Stroke (P30NS045776, R01NS045860)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD018655)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, familial Alzheimer's disease, amyloid plaques, tauopathy, neurofibrillary tangles, amyloid hypothesis, presenilin 1 mutations, human neural stem cells, 3D cell culture, human neurons, beta-secretase inhibition, gamma-secretase inhibition, tau phosphorylation, drug screening model
- MeSH terms
- Alzheimer Disease, Cell Differentiation, Drug Evaluation, Preclinical, Extracellular Space, Humans, Microtubule-Associated Proteins, Models, Biological, Phosphorylation, Reproducibility of Results, Amyloid beta-Peptides, Neurites, tau Proteins, Cell Culture Techniques, Glycogen Synthase Kinase 3, Presenilin-1, Neural Stem Cells, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
